• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Akero Therapeutics, Inc. - Common Stock (NQ:AKRO)

54.74 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Akero Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Halper Sadeh LLC Encourages SEE, AXTA, SEMR, AKRO Shareholders to Contact the Firm to Discuss Their Rights
November 20, 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO
November 20, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Halper Sadeh LLC Encourages JAMF, CADE, AKRO, GES Shareholders to Contact the Firm to Discuss Their Rights
November 07, 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
November 07, 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qorvo, Inc. (Nasdaq – QRVO), First Foundation Inc. (NYSE – FFWM), Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD)
November 06, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages AL, FFWM, AKRO, HNI Shareholders to Contact the Firm to Discuss Their Rights
October 30, 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qorvo, Inc. (Nasdaq – QRVO), First Foundation Inc. (NYSE – FFWM), Akero Therapeutics, Inc. (Nasdaq – AKRO), CoreCard Corporation (NYSE – CCRD)
October 29, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC Investigates AKRO, CCRD, PBBK on Behalf of Shareholders
October 22, 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD), PB Bankshares, Inc. (Nasdaq - PBBK), Air Lease Corporation (NYSE – AL)
October 22, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRUE, AKRO, PCH, ATXS on Behalf of Shareholders
October 16, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD), PB Bankshares, Inc. (Nasdaq - PBBK), Air Lease Corporation (NYSE – AL)
October 16, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO
October 10, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates AKRO, CCRD, AL, PBBK on Behalf of Shareholders
October 09, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD), PB Bankshares, Inc. (Nasdaq - PBBK), Air Lease Corporation (NYSE - AL)
October 09, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
AKRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akero Therapeutics, Inc. Is Fair to Shareholders
October 09, 2025
From Halper Sadeh LLC
Via Business Wire
News headline image
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
October 09, 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
October 07, 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO
September 18, 2025
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
August 28, 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
August 14, 2025
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH 
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 08, 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
June 03, 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
May 28, 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
May 10, 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
May 09, 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
May 09, 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference
May 07, 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Long-Term Shareholders Have Rights – If You Hold Akero Therapeutics, Inc. (NASDAQ: AKRO); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Mercury Systems, Inc. (NASDAQ: MRCY); or Virtu Financial Inc. (NASDAQ: VIRT), Contact Grabar Law Office
May 05, 2025
From Grabar Law Office
Via GlobeNewswire
News headline image
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025
April 30, 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap